Tradestie Institutional Equity Comparison Engine

XBI vs CDT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XBI Overall Edge

XBI Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SPDR S&P Biotech ETF (XBI) driven by superior Momentum & Technical, Options & Structure while CDT counters with relative strength in Growth & Margin. Fundamentally, XBI trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, XBI sits in CONSOLIDATION (17th %ile IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
XBI N/M vs CDT N/M Fwd P/E
Growth & Margin Winner CDT
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner XBI
1Y +22.4% vs -86.8% ยท 52W Pos 47% vs 2%
Options & Structure Winner XBI
CONSOLIDATION (17th %ile IV) vs BREAKDOWN (N/A IV)
XBI NYSE Arca
SPDR S&P Biotech ETF
Institutional Equity
$140.18
-2.73% 1D
Market Cap N/A
1M Return -7.56%
1Y Return +22.43%
Forward P/E N/M
Unified AI Score
52.9 / 100 HOLD
Tech 23.0 Fund 51.0 Flow 57.0 Mom 60.0
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
1M Return +76.79%
1Y Return -86.78%
Forward P/E N/M
Unified AI Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XBI +22.43% CDT -86.78% Spread: +109.21 pp (XBI Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
XBI TTM Op. Margin: N/A CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XBI vs CDT. Trailing 12-month operating profitability (XBI N/A vs CDT 0.0%) and valuation multiples (XBI N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XBI (3) vs CDT (5)
Institutional Metric XBI CDT Criterion Row Winner
Market Capitalization Scale N/A $507,528 Larger Scale CDT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth CDT
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin CDT
Net Profit Margin Profitability N/A 0.0% Higher Margin CDT
Return on Equity (ROE) Capital Efficiency N/A -69.7% Higher ROE CDT
52-Week Range Position Momentum 47% ($113โ€“$170) 2% ($0โ€“$11) Stronger Trend XBI
Beta / 30D Volatility Risk Regime 1.17ฮฒ ยท 38% Vol -17.75ฮฒ ยท 10175% Vol Lower Realized Risk XBI
Unified Institutional Score Composite Signal 52.9 / 100 (HOLD) 31.6 / 100 (SELL) Higher Composite XBI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XBI vs CDT Buy Guide
XBI CONSOLIDATION
66d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live XBI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDT BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XBI nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.